Horizon Therapeutics PLC (NASDAQ:HZNP) Expected to Post Earnings of $0.39 Per Share

Share on StockTwits

Analysts predict that Horizon Therapeutics PLC (NASDAQ:HZNP) will report earnings of $0.39 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Horizon Therapeutics’ earnings. The lowest EPS estimate is $0.37 and the highest is $0.41. Horizon Therapeutics posted earnings per share of $0.48 in the same quarter last year, which suggests a negative year-over-year growth rate of 18.8%. The business is expected to issue its next earnings results on Wednesday, August 14th.

On average, analysts expect that Horizon Therapeutics will report full-year earnings of $1.74 per share for the current year, with EPS estimates ranging from $1.58 to $1.86. For the next financial year, analysts forecast that the business will report earnings of $2.05 per share, with EPS estimates ranging from $1.80 to $2.29. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Horizon Therapeutics.

Horizon Therapeutics (NASDAQ:HZNP) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.20. The firm had revenue of $280.00 million for the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. The firm’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.03 EPS.

A number of research analysts recently issued reports on the company. Cantor Fitzgerald raised their price target on Horizon Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. TheStreet downgraded Worthington Industries from a “b-” rating to a “c+” rating in a research note on Monday, June 10th. Piper Jaffray Companies set a $195.00 price target on Cummins and gave the stock a “buy” rating in a research note on Thursday, April 4th. Mizuho set a $27.00 price target on Horizon Therapeutics and gave the stock a “hold” rating in a research note on Wednesday, May 8th. Finally, BMO Capital Markets set a $13.00 price target on Vale and gave the stock a “hold” rating in a research note on Thursday, April 4th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $31.91.

In other Horizon Therapeutics news, EVP Vikram Karnani sold 13,111 shares of Horizon Therapeutics stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $25.02, for a total value of $328,037.22. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeff Kent sold 3,620 shares of Horizon Therapeutics stock in a transaction that occurred on Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total value of $89,196.80. The disclosure for this sale can be found here. Company insiders own 4.10% of the company’s stock.

Several hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Horizon Therapeutics by 165.1% in the first quarter. FMR LLC now owns 5,205,217 shares of the biopharmaceutical company’s stock worth $137,575,000 after buying an additional 3,242,071 shares during the period. Norges Bank acquired a new stake in shares of Horizon Therapeutics in the fourth quarter valued at about $46,493,000. D. E. Shaw & Co. Inc. lifted its stake in shares of Horizon Therapeutics by 63.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock valued at $65,840,000 after buying an additional 1,312,142 shares during the period. Victory Capital Management Inc. bought a new stake in shares of Horizon Therapeutics in the first quarter valued at about $27,663,000. Finally, Two Sigma Investments LP lifted its stake in shares of Horizon Therapeutics by 84.1% in the fourth quarter. Two Sigma Investments LP now owns 1,763,588 shares of the biopharmaceutical company’s stock valued at $34,461,000 after buying an additional 805,770 shares during the period. Institutional investors own 89.09% of the company’s stock.

NASDAQ:HZNP traded up $0.32 during mid-day trading on Tuesday, reaching $23.84. 1,585,915 shares of the stock were exchanged, compared to its average volume of 1,913,758. The company has a 50 day moving average of $23.91. The firm has a market capitalization of $4.41 billion, a PE ratio of 13.03, a P/E/G ratio of 1.35 and a beta of 1.03. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.74 and a quick ratio of 1.68. Horizon Therapeutics has a 1 year low of $16.56 and a 1 year high of $29.44.

About Horizon Therapeutics

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Featured Story: Should I follow buy, hold and sell recommendations?

Get a free copy of the Zacks research report on Horizon Therapeutics (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Therapeutics (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

JPMorgan Chase & Co. Increases AvalonBay Communities  Price Target to $224.00
JPMorgan Chase & Co. Increases AvalonBay Communities Price Target to $224.00
Brightsphere Investment Group  Lifted to “Hold” at Zacks Investment Research
Brightsphere Investment Group Lifted to “Hold” at Zacks Investment Research
PLDT  Rating Lowered to Hold at Zacks Investment Research
PLDT Rating Lowered to Hold at Zacks Investment Research
AtriCure  Stock Rating Lowered by Northland Securities
AtriCure Stock Rating Lowered by Northland Securities
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Bradesco Corretora Reiterates “Neutral” Rating for Ternium
Meridian Bioscience  Rating Lowered to Sell at ValuEngine
Meridian Bioscience Rating Lowered to Sell at ValuEngine


 
© 2006-2019 Zolmax.